Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) has launched the #Type1TestedPledge campaign during Diabetes Awareness Month to enhance awareness of type 1 diabetes (T1D) risk factors and the significance of early screening. T1D affects 1.6 million Americans, with many cases going undetected. The campaign aims to encourage the community to partake in discussions about T1D and promote screening among those with a family history. Provention Bio highlights that early detection can prevent severe complications associated with T1D.

Positive

• Launch of #Type1TestedPledge campaign aims to raise awareness and promote early screening for type 1 diabetes (T1D).
• Campaign supports community engagement through partnerships with patient advocacy organizations.

Negative

• None.

RED BANK, N.J., Nov. 9, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it's putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November. The company is calling on the T1D community to take the #Type1TestedPledge to spread awareness about risk factors and the importance of screening people with a family history of T1D for early-stage, pre-symptomatic disease. Screening may reduce the risk of serious complications and life-threatening events such as diabetic ketoacidosis. It can also allow time to prepare for the onset of clinical disease and a lifetime of insulin administration and glucose monitoring.

T1D is an autoimmune disease affecting 1.6 million Americans and another 300,000-400,000 Americans have early-stage disease, which may have no symptoms and go unnoticed while the insulin-producing cells are progressively destroyed. Family history puts people at up to 15 times greater risk of developing T1D. The disease can be detected in the earliest stages - before symptoms occur - through a blood test for certain autoantibodies. Data show 75% of people with these autoantibodies will go on to develop clinical, or insulin-dependent, T1D within five years, and their lifetime risk is almost 100%.

"The #Type1TestedPledge is deeply rooted in Provention Bio's mission to seek out and target autoimmunity early. It builds on our successful 'Type 1 Tested' campaign and national effort to redefine patient care in T1D," said Jason Hoitt, Chief Commercial Officer, Provention Bio.

The campaign will be featured on Type 1 Tested and other social media and digital channels, with support from leading patient advocacy organizations. People can get involved with the campaign by pledging to:

• Learn more about the Type 1 Test
• Start a conversation about T1D risk and early screening
• Get Type 1 Tested if you have a family history of T1D
• Connect with the T1D community

Go to www.type1tested.com to learn more about the #Type1TestedPledge campaign and join the Type 1 Tested community on Instagram and Facebook.

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease, and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-puts-type-1-diabetes-to-the-test-with-pledge-campaign-for-diabetes-awareness-month-301419109.html

SOURCE Provention Bio, Inc.

FAQ

What is the #Type1TestedPledge campaign by Provention Bio (PRVB)?

The #Type1TestedPledge campaign is an initiative launched by Provention Bio to raise awareness of type 1 diabetes (T1D) risk factors and encourage early screening.

How does early screening benefit individuals at risk for type 1 diabetes (T1D)?

Early screening can identify pre-symptomatic T1D, potentially preventing serious complications and allowing for better preparation for treatment.

What is the target audience for Provention Bio's #Type1TestedPledge campaign?

The target audience includes individuals with a family history of T1D and the broader type 1 diabetes community.

How prevalent is type 1 diabetes (T1D) in the United States?

Type 1 diabetes affects approximately 1.6 million Americans, with an additional 300,000-400,000 having early-stage disease.

What are the key risks identified in the #Type1TestedPledge campaign?

Key risks include the potential for developing T1D, especially in individuals with a family history, which increases their risk by up to 15 times.